Track topics on Twitter Track topics that are important to you
Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 manufacturing plants and 4 research centres situated in Parma (Italy), Paris, Rockville (Maryland - USA) and Chippenham (UK). The Company's history of continual development is founded on concepts which constitute the basis for its management: strategic innovation, internationalization and ability to plan taking care in the creation of socially compatible economic values.
Thanks to the process of internationalization and strategic alliances with international pharmaceutical groups, Chiesi Group drugs and technologies are today distributed in over 65 countries. The Group employs over 3,800 people, approximately 320 of whom are researchers who work in the four Research and Development laboratories, and approximately 600 of whom are employed in the manufacturing sites in Italy, France and Brazil.
Via Palermo, 26/A
Phone: +39 0521 279
Fax: +39 0521 774468
An absence of comprehensive data did not prevent Italian family-owned drugmaker Chiesi Farmaceutici from…
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Protalix to receive $25 million upfront, an additional up to $20 million in development costs and an additional up to $760 million in potential regulatory and commercial milestone payments for the U....
Protalix BioTherapeutics said today it has granted Chiesi Farmaceutici exclusive U.S. rights to develop and commercialize the Phase III Fabry disease treatment PRX-102 (pegunigalsidase alfa), in an ex...
It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of th...
Chiesi's marketing application for Lamzede, or velmanase alfa, as long-term enzyme replacement therapy for the treatment of n -More-
European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosi...
Chiesi, new partner in d·HEALTH Barcelona program28.05.2018
CUROSURF (poractant alfa)Intratracheal Suspension
CHF5633 (Chiesi Farmaceutici, Italy) is a synthetic surfactant developed for respiratory distress syndrome replacement therapy in pre-term newborn infants. CHF5633 contains two phospholipids (dipalmit...
Triticum vulgare has been extensively used in traditional medicine thanks to its properties of accelerating tissue repair. The specific extract of Triticum vulgare manufactured by Farmaceutici Damor (...
Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...
Evaluation of the filler performance on the nasolabial folds of Aliaxin® EV with and without lidocaine 0.3%: comparison within subjects (half face method)
Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to ag...
The rational of intra-articular viscosupplementation is based on both the biological and mechanical properties of HA, which exerts positive effects on the modulation of the entire joint en...
Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...
The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...
Fidia Farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based...
Dompé is one of the most dynamic, flexible and innovative set-ups on the European scene.Successful in the traditional pharmaceutical market in the treatment of respiratory and osteoarticular patholog...
We have published hundreds of Chiesi Farmaceutici S.p.A. news stories on BioPortfolio along with dozens of Chiesi Farmaceutici S.p.A. Clinical Trials and PubMed Articles about Chiesi Farmaceutici S.p.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Farmaceutici S.p.A. Companies in our database. You can also find out about relevant Chiesi Farmaceutici S.p.A. Drugs and Medications on this site too.